39 results about "Whole cell vaccine" patented technology

Whole-cell vaccines and methods for enhancing the immunogenicity of cellular microorganisms for use in producing protective immune responses in vertebrate hosts subsequently exposed to pathogenic bacteria or for use as vectors to express exogenous antigens and induce responses against other infectious agents or cancer cells. The present invention involves an additional method of enhancing antigen presentation by intracellular bacteria in a manner that improves vaccine efficacy. After identifying an enzyme that has an anti-apoptotic effect upon host cells infected by an intracellular microbe, the activity of the enzyme produced by the intracellular microbe is reduced by expressing a mutant copy of the enzyme, thereby modifying the microbe so that it increases immunogenicity.

The invention relates to a drug and a tumor whole-cell vaccine for treating or preventing tumor, and preparation methods and applications of the drug and the whole-cell vaccine, and belongs to the fields of bioengineering and biological immunology. The invention provides a drug with good effect for treating or preventing tumor and a tumor whole-cell vaccine. The drug comprises the tumor whole-cell vaccine, a cation liposome, and recombinant plasmid for encoding interleukin-15 gene. The drug has the dual actions of tumor prevention immunization and anti-tumor immune treatment, and has durable action and obvious tumor prevention or treatment effect.

Provided herein, inter alia, are cell media compositions and whole cell vaccines comprising recombinant cells expressing IL-15, IL-15Rα, and CD80 capable of treating and preventing relapse in individuals diagnosed with or thought to have leukemia as well as methods for using the same.

The invention relates to a bacterium coreless vaccine used for the fish aquaculture, in particular to a Vibiro anguillarum coreless vaccine and the preparation method thereof. The Vibiro anguillarum is an engineering bacteria construction carrier and then turn, foster, filter and purify the carrier to prepare the coreless vaccine. The adoption of the Vibiro anguillarum coreless vaccine retains the complete antigenic determinant of the Vibiro anguillarum cell membrane, overcomes the defect of antigenic damage caused by the traditional physical and chemical vaccine inactivation way. By immunizing the fish by oral administration and injection, the invention can better protect the fish compared with the traditional inactive cell vaccine. In addition, the invention has commercial development value due to low cost and broad prospect in developing the polyvalent vaccine and preventing various diseases as a vaccine carrier.

A cancer vaccine technology is provided which knocks out expression of cell surface immune checkpoint proteins, to facilitate their processing by immune cells, and optionally by knocking-in the expression of cytokines to boost immune response. Non-replicating tumor cells lacking cell surface CD47 are highly effective immunizing agents against subcutaneous mouse melanoma. Whole-cell vaccines inhibited tumor growth, and immunophenotyping showed a dramatic increase in activated effector cell subsets and M1-type macrophages aided by a significant reduction in the tumor-associated macrophage and myeloid derived suppressor cell compartments. A remarkable downregulation of cell surface CD47 was observed in the tumors that did escape after vaccination with genetically modified cells, suggesting the intricate involvement of CD47 in a prophylactic situation. An effective vaccination strategy to increase tumor-specific immune response in solid tumors is provided to improve the outcome of cancer immunotherapy.

Whole-cell vaccines and methods for their use in producing protective immune responses in vertebrate hosts subsequently exposed to pathogenic bacteria. The present invention involves a method of enhancing antigen presentation by intracellular bacteria in a manner that improves vaccine efficacy. After identifying an enzyme that has an anti-apoptotic effect upon host cells infected by an intracellular microbe, the activity of the enzyme is reduced, thereby modifying the microbe so that it increases immunogenicity. Also, the present invention provides a method of incrementally modifying enzyme activity to produce incrementally attenuated mutants of the microbe from which an effective vaccine candidate can be selected.

The invention relates to a radioresistant lung cancer whole-cell vaccine, and a preparation method and application thereof, and particularly establishes a radioresistant lung cancer cell strain with obviously higher radioresistance, of which the collection number is CCTCC No.C201537. The animal experiment proves that the lung cancer whole-cell vaccine prepared by using the cell strain has the obvious actions on inhibiting mouse lung cancer tumors from growth, promoting transplantation tumor apoptosis and lowering the expression of the transplantation tumor immunologic escape PDL-1 protein; and when being combined with CpG ODN, the lung cancer whole-cell vaccine has more obvious actions on tumor inhibition, and part of mouse tumors completely disappear, thereby obtaining permanent specific antitumor effects. The invention provides a new idea and method for treating lung cancers and preventing postoperative metastasis and relapse.

The invention discloses a rhamnose modified tumor whole-cell vaccine consisting of complete tumor cells, wherein the complete tumor cells have rhamnose antigens on surfaces through a chemical method and lose differentiation and proliferation capacities through inactivation treatment. The tumor vaccine disclosed by the invention is simple in preparation, good in stability and low in cost, can overcome the defects of poor effect, easy relapse and great side effect of an existing tumor treatment method, is safer and more effective to treat tumors, is theoretically suitable for treatment of various malignant tumors and cancers of human, and has very broad application prospects.

A vaccine composition for birds comprising as an active ingredient a structure containing O-antigen derived from Gram-negative bacteria, provided that said structure does not contain a whole cell, and a process for preparing the same are provided. By using a structure containing O-antigen (e.g. lipopolysaccharide) derived from Gram-negative bacteria as an active ingredient in accordance with the present invention, alleviation of inoculation reaction and reduction in an amount of injection are attained as compared to the conventional whole-cells vaccine to thereby allow for the increase in the number of other antigens to be mixed therewith.

The invention relates to a vaccine for fish, in particular to a whole-cell vaccine prepared from Aeromonas caviae or a vaccine prepared from exotoxin of the Aeromonas caviae, and application thereof in preventing fish diseases. A strain is obtained through the separation from a focus of southern catfish, is the Aeromonas caviae through the identification, is named DKN-1, and was preserved in China Center for Type Culture Collection on Sep 12th, 2007, and a preserving number of the strain is CCTCC NO: M207146. The use of the vaccine can stimulate fish bodies to produce the immunity against ulcer syndrome, and strengthen the resistance against diseases.

The invention discloses a somatic whole-cell vaccine composition for treating chronic diseases. The composition includes somatic cells, monoclonal antibodies, cell factors, a cell cracking agent and normal saline. The invention also discloses a preparation method of a somatic whole-cell vaccine for treating the chronic diseases, and the method includes the steps of collecting, separation, extraction, culturing, amplification, collecting, splitting decomposition, purification and agent preparation. The vaccine is prepared by utilizing variational cells in blood of the human body and can stimulate the human body to carry out a specific immunity reaction on variational antigens, correspondingly immune cells and the monoclonal antibodies both of which have a specific lethal effect are generated and circularly identify and kill the variational cells carrying the variational antigens in the human body, metabolic waste generated by the variational cells are removed, and the purposes of preventing relapse of the diseases and improving the living quality are achieved. At present, it is proved by experiments that the vaccine has a great therapeutic effect on patients suffering from diabetesand skin diseases.

The invention relates to a whole-cell vaccine for inhibiting or preventing melanoma, and a preparation method for the whole-cell vaccine, in particular to a preparation method for a tumour vaccine which has a function of improving an immune response and is co-cultured by a new antigen cell and a dendritic cell, and application. The vaccine is characterized in that an MLH-1 gene with a DNA (deoxyribonucleic acid) repairing function is knocked out in a melanoma cell, so that a tumour cell generates mutation in a cell replication process so as to express a non-autologous antigen easy in immune cell recognition. After the mutated tumour cell is processed, the mutated tumour cell and a DC (Dendritic cell) are co-cultured, and therefore, costimulatory proteins expressed on the surface of the DCare obviously improved. The whole-cell vaccine prepared by the method obviously improves the immune response in the body of a mouse, in-vivo IFN-G (interferon-G) and TNF-A (Tumour necrosis factor-a) is improved than a non-injected vaccine group, and therefore, the whole-cell vaccine performs an important function of treating the tumor.

A method for increasing the presentation of ETEC CS6 antigen on cell surface, comprising the step of contacting cells expressing said antigen with an aqueous solution comprising 0.6-2.2 percent phenol by weight, such that the presentation of said antigen is increased by at least 100%. A method for the manufacture of a killed whole cell vaccine for immunization against CS6-expressing ETEC. Cells and vaccines obtainable by the above methods.